MI-EATON
Intelligent power management company Eaton today announced its comprehensive suite of safety-focused electrified vehicle (EV) technologies will be on display June 18-20 in Hall 10-A36 at The Battery Show Europe in Stuttgart, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611322422/en/
Eaton plans to show its suite of safety-focused electrified vehicle (EV) technologies June 18-20 at The Battery Show Europe in Stuttgart, Germany. (Photo: Business Wire)
“While EV adoption continues to increase, we are helping our global customers meet the growing demand with innovative new technologies,” said Mark Schneider, president, Eaton’s eMobility business. “Safety is always a priority, whether the vehicle is powered by gasoline or electricity, and our EV solutions ensure occupants and the vehicle itself remain secure.”
Breaktor a pioneering high-voltage EV protection device
Eaton’s Breaktor® circuit protection technology combines the function of fuses, pyro switches, and contactors into a single coordinated and resettable device. As electric vehicle power levels increase, Breaktor solves the ever-increasing coordination challenge between fuses and contactors and offers extremely fast, safe and reliable protection for high-power battery and inverter systems.
3-in-1 battery vent valve improves battery pack leak testing
Eaton’s 3-in-1 battery vent valve is the first-to-market solution that is capable of three unique functions. In addition to passive and active venting, to provide overpressure relief for the vehicle’s battery pack, it includes an industry first battery-case leak-check mechanism.
It can open up during testing, allowing battery makers to completely leak-check the fully assembled battery pack with the valve in place. This provides customers with the peace of mind that all sealing surfaces of the battery pack are fully tested against water ingress. This Eaton-developed technology improves the safety of vehicles during normal operation and in the event of flooding situations.
The vent valve is precisely and flexibly designed to meet specific opening pressures and optimize venting. Its spring-based actuation technology allows Eaton to accommodate different opening pressure requirements with the same valve design to drive economies of scale.
Fuel tank isolation valve releases pressure in hybrid-electric vehicles
Eaton’s next-generation fuel tank isolation valve (FTIV) releases pressure in the gas tank of a hybrid-electric vehicle since the gas engine in a hybrid vehicle does not operate continuously. Pressure has to be released when the vehicle is in electric mode, and when refueling it’s important the tank is depressurized to avoid spit back.
High Power Lock Box terminals provide protection against the elements
Eaton’s High Power Lock Box (HPLB) terminals, which serve as the interface to a conductor and create a point where external circuits can be connected, are ideal for current and future EV solutions. They have numerous benefits over competitive solutions, including a space-saving profile, superior performance, cost savings, and reduced manufacturing complexity. They also provide efficiency, reliability and protection against the elements.
Eaton Bussmann series fuses optimized for high-powered electrified vehicles
Eaton Bussmann® series fuses feature ratings of up to 1,000 volts of direct current (VDC) and up to 600 amps, enabling them to meet the requirements for use in high-powered EVs.
Eaton's hybrid and EV fuses are designed to manage and protect the charging systems of electric commercial, passenger and high-performance vehicles such as sports cars and large sport-utility vehicles.
Learn more about Eaton’s EV solutions.
Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace, and mobility markets. We are guided by our commitment to do business right, to operate sustainably, and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy sources, helping to solve the world’s most urgent power management challenges, and building a more sustainable society for people today and generations to come.
Eaton was founded in 1911 and has been listed on the New York Stock Exchange for more than a century. We reported revenues of $23.2 billion in 2023 and serve customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611322422/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release
IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 14:00:00 CEST | Press release
Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost Savings Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 14:00:00 CEST | Press release
Four-year data show nearly 9 in 10 RMS patients remained free from progression independent of relapse activity (PIRA)Results highlight the potential of MAVENCLAD to reduce neurodegeneration and neuroinflammation beyond established clinical efficacy outcomes in RMSEvidence suggests that MAVENCLAD effectiveness could be driven by peripheral and central effects without requiring continuous immunosuppression Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in
Kinectrics Significantly Increases Isotope Production Capacity to Meet Growing Global Demand17.9.2025 13:30:00 CEST | Press release
Kinectrics, a division of BWX Technologies Inc. (NYSE: BWXT), announced today the completion of a major expansion to its isotope production capabilities, reinforcing its role as a global supplier of highly enriched stable isotopes and establishing the only North American source for Yb-176, reducing the reliance on foreign material for life-saving cancer treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917450864/en/ Travis Besanger, Kinectrics VP of Medical Isotopes, speaking within the new Isotope Separation Production Facility at Kinectrics Headquarters in Toronto, Canada. Kinectrics commissioned four new 2nd generation Electromagnetic Isotope Separator (EMIS) units, which will boost its annual production capacity to over 500 grams of Ytterbium-176 (Yb-176), the precursor for Lutetium-177 (Lu-177), by the end of the year. This scaled output will support over 150,000 patient treatments annually. Lu-177 is a medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom